Relative expression levels of PD-L1 also indicated this protein to be a potential therapeutic target, however, since ICIs of PD-L1 are already approved for therapy in RCC and have shown therapeutic efficacy, we chose to focus on TGF-β1 instead. This evidence concerns the gene TGFB1 and renal cell carcinoma.